Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33…
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to…
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
May 30, 2025 07:00 ET | Source: Cartesian Therapeutics, Inc. FREDERICK, Md.,…
Teva Reaffirms Pivot to Growth Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on…
Mavenir Collaboration with Three UK and Red Hat Doubles Glasgow 5G Speeds in UK-First Open RAN Small Cells Roll-Out
Mavenir Open vRAN and O-RAN compliant small cells central to success of…
TAQA Saudi Arabia Announces CEO Transition as Part of Strategic Growth Agenda
Company prepares for the next phase of profitable growth, market expansion, and…
Hexaware Wins Brand of the Year Awards 2025 for Strategic Growth and Innovation
MUMBAI, India, May 28, 2025 /PRNewswire/ -- Hexaware Technologies (NSE: HEXT), a…
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the…
Australia Delivers Certainty for US Biotechs in 2025:Avance Clinical Offers Fast Start-Up, Regulatory Predictability, and R&D Rebates
ADELAIDE, Australia, May 26, 2025 (GLOBE NEWSWIRE) -- As regulatory uncertainty grows…